Validation of antimicrobial drug target selection using X-ray crystallographic methods

使用 X 射线晶体学方法验证抗菌药物靶点选择

• 批准号: 411306-2010
• 负责人: James, Michael
• 金额: $ 1.82万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2010
• 资助国家: 加拿大
• 起止时间: 2010-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=472954
• 关键词: Validation; antimicrobial; drug; target; selection

Indel Therapeutics Inc. is a Vancouver-headquartered antibiotic drug discovery company aiming to develop a pipeline of anti-microbials using its proprietary antibiobiotic target selection platform. Indel has embarked upon a collaborative venture with the laboratory of Dr. Michael James at the University of Alberta to experimentally validate the Indel platform. The James laboratory specializes in determining the X-ray crystal structures of proteins and protein-nucleic acid complexes and is a world leader in the field. The molecular structure of high-priority targets identified by the Indel process will be determined. This knowledge will enable virtual screening to identify potential inhibitors of the target protein. Subsequent molecular structures of target-inhibitor complexes will reveal whether Indel targeting predictions are correlated with what is observed experimentally. Going forward, the structural insights will allow crystallographers to rationally guide the improvement of the inhibitor to increase its potency and specificity. Additionally, the development of a robust assay of a target's activity will enable Indel to develop a high throughput screen to test inhibitors that emerge from its medicinal chemistry arm.

Indel Therapeutics Inc.是一家总部位于温哥华的抗生素药物发现公司，旨在利用其专有的抗生素靶标选择平台开发一系列抗微生物药物。Indel已经开始与阿尔伯塔大学Michael James博士的实验室合作，对Indel平台进行实验验证。詹姆斯实验室专门研究蛋白质和蛋白质-核酸复合物的x射线晶体结构，在该领域处于世界领先地位。将确定Indel过程确定的高优先级目标的分子结构。这些知识将使虚拟筛选能够识别目标蛋白的潜在抑制剂。靶标抑制剂复合物的后续分子结构将揭示Indel靶向预测是否与实验观察到的相关。展望未来，对结构的了解将使晶体学家能够合理地指导抑制剂的改进，以提高其效力和特异性。此外，对靶标活性的稳健分析的发展将使Indel能够开发高通量筛选来测试其药物化学部门产生的抑制剂。